Today we published our third quarter financial results, which are a powerful demonstration of the impact of our Group strategy, which launched almost a year ago. Our sales grew by 14.9% last quarter, taking our year-to-date (YTD) growth to 12.3%. As a result, we are yet again increasing our guidance for 2021 to greater than 11%. These positive figures are the result of growth in our Specialty Care portfolio, notably in our oncology portfolio.
These strong results come at an exciting moment for Ipsen. We’ve added two new partnerships to our pipeline in the last quarter. The first is with Exicure to research, develop, and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington’s disease and Angelman syndrome. The second is with Accent Therapeutics to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program, reinforcing our expansion into hematological malignancies, with a focus on acute myeloid leukemia. In total, we have signed four exciting new partnerships since July.
As we continue to implement our strategy, Focus. Together. For patients & society, we are guided by clear objectives: to maximize our brands, to build our pipeline, to deliver efficiencies and to boost our culture of collaboration and excellence. We will continue to go above and beyond for the people living with unmet medical needs and to proactively contribute to our communities and to society as a whole.
Find more information on our Q3 results here.
